Latest Commercialisation News

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

InteliCare Holdings has secured a binding agreement to trial its AI-driven platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy within Victoria’s aged care sector.

IDT Australia reports a robust 30% jump in quarterly revenue to $4.1 million, driven by strong contract wins and a $62 million pipeline of open proposals, signaling sustained growth in pharmaceutical manufacturing.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.

Iondrive Limited confirms strong financial metrics for its proprietary DES battery recycling technology, progressing pilot plant development and divesting exploration assets to sharpen focus on commercialisation.

GreenHy2 Limited reports a strategic push in Europe with new contracts for its advanced supercapacitor and hydrogen storage technologies, alongside a cash position of $814K and four quarters of funding runway.

Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.

Decidr AI Industries signals a strategic pivot to AI with a successful $11 million capital raise, new multi-year contracts, and expanded global partnerships, driving early commercial traction and robust e-commerce growth.

Murray Cod Australia Ltd reports a remarkable 192% biomass increase, setting the stage for expanded domestic and international sales from May 2025. The company also advances sustainability certifications and strengthens its board to support growth.

Buxton Resources reports a 345% increase in contained graphite at its Graphite Bull Project and confirms IGO's $5.35 million commitment to expand its Copper Wolf JV interest to 70%.

Osteopore Limited reported a robust 26% quarter-on-quarter revenue increase in Q1 CY25, bolstered by a key Singapore subsidy listing and a strategic pivot away from its dental project to sharpen commercial focus.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.